New device for rectal cancer under the microscope

NCT ID NCT07501845

Recruiting now Knowledge-focused Sponsor: Maastricht Radiation Oncology Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is collecting information from up to 999 people with rectal cancer who are treated with a special device called the MAASTRO HDR applicator. The goal is to learn how well it works and what side effects it causes, so doctors can improve future treatments. Participants will be followed for up to 10 years to track cancer control and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MAASTRO HDR rectal applicator (a device for high-dose-rate contact brachytherapy)
What this could lead to: If successful, this could help doctors better understand how to use this applicator to treat rectal cancer while sparing the rectum, potentially improving patient outcomes.
What could go wrong: This is an observational registry, not a controlled trial, so it cannot prove the treatment works. Results may take years and might not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rectal cancer rectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECTAL CANCER

Contacts and locations

Locations

Maastro
RECRUITING

Maastricht, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.